Cystic Fibrosis Clinical Trial
— MUKADOOfficial title:
Peer-supporting for Teenagers With Cystic Fibrosis in a Process of Transition of Care From Paediatric to Adult Services : a Mixed-method Pilot Study to Assess the Feasibility of the Peer-support Intervention
In patients with cystic fibrosis, a deterioration in lung function around age 18, the age of transfer from pediatrics to adult care services, has been observed. Transfer is only one step in a transition process from pediatric to adult care taking place from age 12 to 24. Adolescence is a period of identity construction during which the disease alters self-image and self-esteem, and a period of empowerment in the management of the disease involving a re-appropriation of it. During this period, coping strategies and psychosocial skills are important to face all the issues that the adolescent encounters. Interventions for youth with chronic illnesses rarely incorporate this dimension. Peer support or peer-mentoring is one avenue for developing these coping skills. Peer support encompasses mutual support between people who are coping or have coped with similar challenging life experiences. Individuals with similar experiences would represent more credible role models to stimulate positive change in their peers. The function of peer support are to provide emotional, experiential, informational support.The effect of peer support improves social integration, coping skills, sense of self-efficacy of the peers being helped. Promotion of healthy youth behaviors by youth is the most widely evaluated youth engagement strategy in the community health sector. Peer-assisted devices have been tested to improve medication adherence and health status with youth with juvenile arthritis, asthma, and liver transplant recipients. By sharing their experience of a successful transition, young adults with cystic fibrosis may be able to help their adolescent peers better understand this transition. Our hypothesis is that implementing peer support with adolescents with cystic fibrosis improves their sense of self-efficacy, a dimension of coping skills.To our knowledge, there are no research studies on peer support in cystic fibrosis in France or abroad. Patients are recognized as partners capable of sharing their experiential knowledge with patients with a similar disease. But this raises questions about the recruitment, supervision, preparation for peer-help and the role of these patients; about the effects of their involvement for themselves (valorization, anxiety) and for their peers (re-assurance, feeling of personal effectiveness). This justifies conducting an exploratory study to assess the feasibility of a peer-support intervention for youth with cystic fibrosis.
Status | Not yet recruiting |
Enrollment | 88 |
Est. completion date | September 1, 2026 |
Est. primary completion date | September 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 24 Years |
Eligibility | Concerning the patient /mentee: Inclusion Criteria: - patient affected by cystic fibrosis - patient able to understand and read French - patient from 15 to 19 years , in a process of transition on paediatric care to adult care - with a follow-up on a paediatric Cystic Fibrosis Centers Competences (CRCM) - did not participate in the Phase 1 co-construction workgroup - affiliated to the social security system - having agreed to participate and signed the consent for an adult patient, or legal guardian having agreed to participate and signed the consent for a minor patient Exclusion Criteria: - patient with transplant - patient with cystic fibrosis transmembrane regulator-related disorders (CFTR RD) or Screen Positive Inconclusive Diagnosis (SPID) Cystic Fibrosis - patient with a curator, tutor or under the protection of a conservator - pregnant or breastfeeding patient Concerning the mentor/peer-supporter (post period): Inclusion Criteria * : - affected cystic fibrosis - able to understand and read French - young adult, 19 to 24 years old - with a follow-up on the adult CRCM (transition completed) - affiliated to the social security system - have agreed to participate and signed the consent form - did not participate in the Phase 1 co-construction workgroup Exclusion Criteria * : - patient with transplant - patient with CFTR RD or SPID Cystic Fibrosis - patient with a curator, tutor or under the protection of a conservator - pregnant or breastfeeding patient |
Country | Name | City | State |
---|---|---|---|
France | CRCM Lyon pédiatrie - Hôpital Femme Mère Enfant, Hospices Civils de Lyon | Bron | |
France | CRCM Grenoble adulte - Hôpital Albert Michallon | Grenoble | |
France | CRCM Grenoble pédiatrie - Hôpital Albert Michallon | Grenoble | |
France | CRCM Lyon adulte - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon | Pierre-Bénite |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 6 months | Change in Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 6 months. The CFQ-R includes 34 cystic fibrosis-specific quality of life items, scored on a 4-modality scale, and exploring 9 dimensions including perceived health, burden of treatment, self-image (and body image in particular), emotional state, and social interaction that are particularly impacted by the transition period. The responses allow us to establish a score on a scale of 0 to 100, the higher the score the better the quality of life. | Baseline ; at 6 months | |
Primary | Change from baseline Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 3 months | Change in Quality of life of adolescents in transition, measured by the French version of the Cystic Fibrosis Questionnaire - Revised (CFQ-R) at 3 months. The CFQ-R includes 34 cystic fibrosis-specific quality of life items, scored on a 4-modality scale, and exploring 9 dimensions including perceived health, burden of treatment, self-image (and body image in particular), emotional state, and social interaction that are particularly impacted by the transition period. The responses allow us to establish a score on a scale of 0 to 100, the higher the score the better the quality of life. | Baseline ; at 3 months | |
Secondary | Effect of peer support model during pediatric-adult transition, assessed in adolescents (comparison between sponsored adolescents and non-sponsored adolescents) on their sense of self-efficacy | Adolescents' sense of self-efficacy (Phase 2 primary endpoint), measured by the French version of the generic 10-item General Self-Efficacy Scale (GSE) rated on a 4-modality scale (not at all true, barely true, moderately true, totally true). | Measurement at inclusion, 3 months and 6 months | |
Secondary | Effect of peer support model during pediatric-adult transition, assessed in adolescents (comparison between sponsored adolescents, included in post period, and non-sponsored adolescents, included in pre period) on management and therapeutic adherence | Management and therapeutic adherence, measured by a cystic fibrosis-specific adherence self-assessment questionnaire and focusing on the patient's perceived adherence to the respiratory (physical therapy and therapeutics), digestive and nutritional components of cystic fibrosis management. This Cystic Fibrosis Compliance questionnaire will be used in its French version. Indeed, it has already been translated according to a standard translation-re translation procedure by the same research study in a previous study (N° 2019-A01029-48, favorable opinion of the Ethic committee West IV - Nantes on 10/09/2019). This previous study is still in progress and will be published at the end of the study. | Measurement at inclusion, 3 months and 6 months | |
Secondary | Effect of peer support model during the pediatric-adult transition, assessed in adolescents (comparison between sponsored adolescents, included in the post period, and non-sponsored adolescents, included in the pre period) on sense of social integration. | Sense of social integration, measured by the 5 items of the "social integration and support" dimension of the validated French version of the Health Education Impact Questionnaire (heiQ).
The items are: 22) If I need help, I have people I can count on; 28) I have enough friends to help me cope with my health problems;31) When I feel sick, my family and the people who take care of me understand what I am going through;35) In general, I feel that my friends and family look after me well;37) I have enough opportunities to talk about my health problems with people who understand me. Responses are rated on a 4-way agreement scale (strongly disagree, disagree, agree, strongly agree). |
Measurement at inclusion, 3 months and 6 months | |
Secondary | Fidelity of peer-assistance process in relation to what was planned (criteria collected in the "after" period only). | Fidelity of the peer-assistance process in relation to what was planned (criteria collected in the "after" period only):
Collection of implementation indicators (grid for collecting the number of contacts between sponsor and sponsored person, the modalities and the themes discussed during the contacts) and qualitative analysis of the content of the exchanges of practices between sponsors during the peer-assistance period. |
From inclusion to the end of pair-aidance, up to 8 months | |
Secondary | Experience (Experience, Satisfaction, Acceptability) of peer support among sponsored adolescents, sponsors, parents and accompanying professionals by individual interviews 1 to 2 months after the end of peer support (collected in the "after" period). | Perceived experience/other effects of peer support by the accompanying professionals, and in particular perceived effects of peer support on their clinical practice.
Experience/other perceived effects of peer support by sponsored adolescents, sponsors, parents. Acceptability and satisfaction of peer support by the participants (sponsored adolescents, sponsors, parents and accompanying professionals): Satisfaction feedback and identification of factors influencing acceptability (participants' sociodemographic characteristics, patients' clinical characteristics, sponsors' previous experiences of supportive roles, status and experiences of accompanying professionals, characteristics of the CRCM). The collection and analysis of these three criteria will be carried out by means of a qualitative study using individual semi-directed interviews (criteria collected in the "after" period only), the content of which will be developed in phase 1. |
From inclusion to the end of pair-aidance, up to 8 months | |
Secondary | Feasibility assessed by the number of questionnaires collected | Feasibility will be validate if a minimum of 90 questionnaires is collected | From inclusion to the end of pair-aidance, up to 8 months | |
Secondary | Feasibility assessed by the estimation of recruitment capacity | Recruitment capacity will be validate if a minimum of 30 patients (15 during each period) is included | From inclusion to the end of pair-aidance, up to 8 months | |
Secondary | Feasibility assessed by the number of resources needed to implement the intervention - Number and profile of accompanying professionals involved | Collection of the profesionnel's profile implicated on the study | From inclusion to the end of pair-aidance, up to 8 months | |
Secondary | Feasibility assessed by the number of resources needed to implement the intervention - Number of exchanges and time needed for supervision and training | Tracking of exchange and the necessary time for training | From inclusion to the end of pair-aidance, up to 8 months | |
Secondary | Feasibility assessed by the number of resources needed to implement the intervention - Collection of material resources needed | Peer support constructed during the period 1 | From inclusion to the end of pair-aidance, up to 8 months | |
Secondary | Feasibility assessed by the estimation of the potential effect of the intervention on the feeling of self-efficacy measured by the GSE | The generic 10-item GSE rated on a 4-modality scale (not at all true, barely true,moderately true, totally true).
The total score is calculated by finding the sum of the all items. For the GSE, the total score ranges between 10 and 40, with a higher score indicating more self-efficacy |
From inclusion to the end of pair-aidance, up to 8 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |